Tuesday, 16 Oct 2018

You are here

Gout Crystal Deposition is Deeper than its Measures

Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT).  The total body urate deposition is even greater in those with higher sUA and evidence of severe disease. 

They enrolled 152 gout patients from New Zealand and USA who were receiving allopurinol ≥300 mg/day for a mean of 5.1 years. MSU crystal deposition was assessed b DECT in the hands/wrists, feet/ankles/Achilles and knees and correlated with sUA levels and gout characteristics.

  • Among allopurinol treated patients, 69.1% had crystal deposition on DECT, with a median total crystal volume of 0.16 cm3.
  • Crystal deposition was found in 46.9% of patients with sUA <6.0 mg/dL and no palpable tophi
  • Crystal deposition was found in 90.0% among those with sUA ≥6.0 mg/dL and tophi.
  • Total volume of crystal deposition was positively associated with sUA ≥6.0 mg/dL, gout flares, tophi and the patients global disease activity scores.

These data are sobering, given the fact that only 30-45% of treated gouty patients will achieve a treat-to-target goal of sUA <6.0 mg/dl. Nearly half of the patients who achieve that goal in this cohort study still had tissue MSU crystal deposition.  

Gout runs deeper than the tophi and is more sinister than the serum urate level measured.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

Usual Allopurinol Doses Insufficient in CKD Patients

Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.

Sleep Apnea Raises Gout Risk

Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.

In a large retrospective cohort study, the adjusted hazard ratio for a new gout diagnosis among individuals with sleep apnea was 1.42 (95% CI 1.29-1.56), according to Milica Blagojevic-Bucknall, PhD, of Keele University in Keele, England, and colleagues.

Adherence to Gout Therapies Painfully Low

A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.